|
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. |
|
|
Honoraria - AstraZeneca; Clovis Oncology; genmab; Immunogen; Merck; Roche; tesaro |
Consulting or Advisory Role - PharmaMar |
Speakers' Bureau - AstraZeneca; Clovis Oncology; pharmamar; tesaro |
Research Funding - Clovis Oncology (Inst); Merck (Inst); PharmaMar (Inst); tesaro (Inst) |
Expert Testimony - Clovis Oncology |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche; TESARO |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Lilly; MSD Oncology; Roche; Sotio; Stryker; Tesaro; Zai Lab |
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Tesaro |
Research Funding - AstraZeneca (Inst); Genmab (Inst); Roche (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GlaxoSmithKline; MSD; Roche; Tesaro |
|
|
Honoraria - Chugai Pharma |
Research Funding - Chugai Pharma (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Carrick Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Medical University of Vienna (Inst); Millennium (Inst); MSD Belgium (Inst); Octimet (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst) |
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche/Genentech; Tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech; Takeda; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche; Tesaro |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Tesaro |
|
|
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro |
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Roche Pharma AG; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Intuitive Surgical; PharmaMar; Roche Pharma AG; Tesaro |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche |
Research Funding - AstraZeneca; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD Oncology; Pfizer; Roche; Sanofi; Tesaro |
Research Funding - Astellas Pharma; Janssen |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Roche; tesaro |
|
Isabelle Laure Ray-Coquard |
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genmab; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro |
Research Funding - Bristol-Myers Squibb; MSD Oncology |
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro |
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA) |